RPAM
ARIA

Rhenman & Partners Asset Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-895,000
Closed -$11.1M – 112
2016
Q4 		$11.1M Buy
895,000
+220,000
+33% +$2.65M 2.13% 13
2016
Q3 		$9.24M Buy
675,000
+50,000
+8% +$502K 1.47% 21
2016
Q2 		$4.62M Buy
625,000
+25,000
+4% +$188K 0.82% 47
2016
Q1 		$3.83M Buy
600,000
+170,000
+40% +$953K 0.76% 50
2015
Q4 		$2.69M Hold
430,000
– – 0.41% 72
2015
Q3 		$2.51M Sell
430,000
-20,000
-4% -$154K 0.4% 67
2015
Q2 		$3.72M Buy
450,000
+63,000
+16% +$557K 0.45% 75
2015
Q1 		$3.19M Sell
387,000
-10,000
-3% -$73.9K 0.54% 64
2014
Q4 		$2.73M Sell
397,000
-26,000
-6% -$163K 0.79% 51
2014
Q3 		$2.28M Buy
423,000
+33,000
+8% +$193K 0.67% 55
2014
Q2 		$2.48M Buy
390,000
+152,190
+64% +$1.05M 0.74% 52
2014
Q1 		$1.92M Sell
237,810
-462,190
-66% -$3.6M 0.58% 62
2013
Q4 		$4.77M Buy
+700,000
New +$3.78M 1.87% 14

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return

Rhenman & Partners Asset Management's ARIA Position: Q1 2017 in Review

Rhenman & Partners Asset Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 895,000 shares — an estimated $11.1M sold.

Rhenman & Partners Asset Management first reported a position in ARIA in Q4 2013 and held it in 13 quarters. The position peaked at $11.1M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Rhenman & Partners Asset Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 895,000 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $11.1M.
  • Rhenman & Partners Asset Management first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 13 quarters.
  • Rhenman & Partners Asset Management's Ariad Pharmaceuticals Inc position peaked at $11.1M in Q4 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.